O’Melveny represented China International Capital Corporation Hong Kong Securities Limited as the sole sponsor and overall coordinator in the IPO. Qyuns Therapeutics Co., Ltd. (2509.HK) announced...
Qyuns Therapeutics’ US$31 Million Initial Public Offering
Folangsi’s HK$155 Million Hong Kong IPO
O’Melveny represented FOLANGSI CO., LTD in the transaction. FOLANGSI CO., LTD (2499.HK) (“FOLANGSI”) announced its approximately HK$155 million initial public offering and listing of H shares...
Beijing UBOX Online Technology Corp.’s HK$233.7 Million Initial Public Offering
O’Melveny assisted Beijing UBOX Online Technology Corp. on the Hong Kong laws. Sidley acted as international legal counsel for the joint sponsors. Beijing UBOX Online Technology...
Beijing Fourth Paradigm Technology’s $150 Million Initial Public Offering
O’Melveny represented the sole sponsor, the coordinators and the underwriters in the transaction. Beijing Fourth Paradigm Technology Co., Ltd. (6682.HK) announced its initial public offering and listing...
Acotec Scientific Holdings’ Partial Offering
O’Melveny advised Acotec Scientific Holdings on the deal. Acotec Scientific Holdings, executed a voluntary partial offering for a majority stake of up to 65% by US-listed Boston...
Beauty Farm’s Hong Kong IPO and Listing
O’Melveny advised Beauty Farm. Clifford Chance has advised the joint sponsors. Shearman & Sterling advised Beijing Xinyu Meiye Holdings Limited as a selling shareholder. Beauty Farm...
Sipai Health Technology’s Hong Kong IPO and Listing
Clifford Chance advised the joint sponsors on the deal while O’Melveny represented Sipai Health Technology Co., Ltd, Eight Roads and F-Prime. The joint sponsors Morgan Stanley...
Cryofocus Medtech’s HK$210 Million IPO
Cooley advised the joint sponsors and underwriters on the deal while O’Melveny represented Cryofocus Medtech (Shanghai) Co., Ltd. Cryofocus Medtech announced its HK$210 million ($27 million) initial...
3D Medicines Inc.’s Listing on the Stock Exchange of Hong Kong
Herbert Smith Freehills advised CICC and CSCI on the deal while O’Melveny recently represented 3D Medicines. CICC and CSCI acted as joint sponsors of 3D Medicines...
Gaush Meditech Limited’s HK$672 Million IPO
Harneys and Tianyuan acted as Cayman Islands counsel to Gaush Meditech Limited, Tian Yuan Law Firm LLP, O’Melveny & Myers and Commerce & Finance Law Offices...
Jenscare Scientific’s Hong Kong IPO
O’Melveny represented Jenscare Scientific Co., Ltd on the deal. Herbert Smith Freehills advised China International Capital Corporation and Citigroup. Jenscare Scientific Co., Ltd. (9877.HK) announced its...
Rainmed Medical’s HK$146 Million IPO and Listing on the Hong Kong Stock Exchange
O’Melveny and Grandall represented Rainmed Medical Limited (2297.HK) on the deal. Herbert Smith Freehills has advised Huatai Financial Holdings. Rainmed Medical Limited (2297.HK) announced its US$19...